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Abstract: Hydroquinine 2,5-diphenyl-4,6-pyrimidinediyl diether 
((DHQ)2Pyr) catalyzed the regio-, diastereo- and enantioselective 
addition of 4-substituted pyrazolones to isatin-derived nitroalkenes, 
providing a variety of chiral alkenyl-pyrazolone adducts containing a 
tetrasubstituted stereocenter bearing an oxindole moiety with 
excellent yields, regioselectivity and diastereoselectivity and 
moderate enantioselectivity (up to 98% yield, >20:1 E:Z ratio dr and 
78% ee). The reaction harness a nitroalkene as an alkenylating agent 
through a Nucleophilic Vinylic Substitution (SNV) reaction. 
Introduction 
Pyrazolones are an important class of nitrogen heterocycles that 
have shown a broad range of biological activities and have 
attracted the attention of the pharmaceutical industry and 
medicinal chemistry.[1] This scaffold is present in a large variety of 
synthetic compounds that exhibit pharmaceuticals properties, 
such as antipyretic, analgesic, neuroprotective, antibacterial, 
etc.[2] In view of the great importance of the pyrazolone skeleton, 
the asymmetric synthesis of pyrazolones bearing a quaternary 
stereocenter have become an attractive goal and many and 
efficient synthetic approaches have been established over the last 
years.[3] So, several asymmetric additions of 4-substituted-
pyrazol-3-ones to different electrophiles have been reported 
employing organo- and metal-catalysts for the synthesis of chiral 
pyrazolones bearing a tetrasubstituted stereocenter at 4 position, 
particulary when the substituent at this position is an alkyl group.[4] 
Nevertheless, the examples in the literature of enantioselective 
synthesis of chiral 4-alkenyl-4-substituted-pyrazolones are 
scarce.[5,6] Feng an coworkers,[5] in 2012, described a Z-selective 
asymmetric 1,4-addition reaction of 4-substituted pyrazolones to 
alkynones catalyzed by an N,N-dioxide-scandium(III) complex 
obtaining 4-alkenyl-4-substituted-pyrazolones with high 
geometric control, high yields, and excellent enantioselectivities 
(Figure 1). In view of the limited examples described, the 
development of other methodologies for the synthesis of chiral  4-









































Figure 1. Enantioselective synthesis of chiral pyrazolones bearing a quaternary 
stereocenter at 4-position. 
On the other hand, 2-oxindole scaffold represents one of the 
most important structures for medicinal and pharmaceutical 
chemistry, due to the plenty of natural products and synthetic 
compounds bearing this motif that present biological activities.[7] 
As an important 2-oxindole structure, unsymmetrical 3-
alkylideneoxindoles[8] are present in various natural products[9] 
and pharmaceutical drugs.[10] We envisioned that the synthesis of 
chiral pyrazolones bearing a 3-alkylideneoxindoles could be 
achieved by nucleophilic vinylic substitution (SNV)[11] of 4-
substituted-pyrazolones and (E)-3-(nitromethylene)indolin-2-
one[12] (Scheme 1). However, the nucleophilic vinylic substitution 
in isatin-derived nitroalkenes have been scarcely studied.[13] Such 
transformation presents three challenges: the regioselectivity of 
the nucleophilic addition (attack at the β-position of the 
nitroalkene or at the α-position), the stereoselectivity of the 1,2-
elimination and the enantioselectivity of the reaction. We have 
recently described a stereoselective addition of pyrazolones to 
isatin-derived nitroolefins in a racemic form.[14] As a part of our 
ongoing interest in the asymmetric addition of pyrazolones,[15] 
herein, we wish to report the addition of 4-substituted pyrazolones  
to isatin-derived nitroalkenes using a (DHQ)2Pyr as an 
organocatalyst through a nucleophilic vinylic substitution (SNV), 
leading to chiral heterocyclic compounds containing both 3-
alkylidene-2-oxindole and pyrazolone moieties bearing a fully 
carbon tetrasubstituted stereocenter with good yields, excellent 
regio- and diastereoselectivity and moderate enantioselectivity 
(Scheme 1). 
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Enantioselective Nucleophilic Vinylic Substitution (SNV)
Challenges: 
a) Regioselectivity (1,4-addition vs to 1,2 addition)




























Scheme 1. Asymmetric synthesis of chiral pyrazolones bearing a 3-alkylidene-
2-oxindole scaffold. 
Results and Discussion 
We initiated our studies by evaluating the nucleophilic addition of 
4,5-dimethyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one 2a to (E)-1-
benzyl-3-(nitromethylene)indolin-2-one (1a) with various 
bifunctional organocatalysts (5 mol%) in toluene at room 
temperature (Table 1). To our delight, quinine A could catalyze 
the reaction and the product 3aa was obtained with 72% yield, 
after 4 hours, with a poor 2:1 E:Z ratio, but with a promising 70% 
ee (entry 1, Table 1). When cinchonidine B was used as catalyst 
similar results were obtained although with lower 
enantioselectivity (47% ee, entry 2). While product 3aa was 
obtained with lower E:Z ratio with hydroquinine C (entry 3) and 
with lower enantiomeric excess (59% ee, entry 4) with quinidine 
D. Cupreine derivative E showed higher E:Z ratio(4:1), but the 
product 3aa was obtained with lower enantioselectivity (41% ee). 
When quinine-derived thiourea F was used, the reaction proceed 
with lower enantioselectivity, however the Takemoto’s thiourea G 
(entry 7) afforded product 3aa with a good diastereomeric ratio of 
7:1 and 52% ee. Next different chiral squaramides were evaluated 
as catalysts (entries  8 and 9), showing that when quinine-derived 
squaramide H  was used, the oxindole 3aa was obtained with 
excellent E:Z ratio (14:1) and 50 % ee. Catalyst (DHQ)2PHAL J 
(entry 10) and (DHQ)2Pyr K (entry 11), were also tested in the 
SNV reaction, obtaining similar E:Z ratio than catalyst H, but 
slighlty better enantioselectivities (53 and 54% ee, respectively). 
Finally, the ammonium salt L, gave practically pure the E isomer 
but with very low enantioselectivity (entry 12). Although quinine A 
gave better enantioselectivity (70% ee) than (DHQ)2Pyr K (54% 
ee), catalyst K gave the best E:Z ratio (16:1), while the 
diastereomeric ratio in the case of the quinine was very poor (2:1). 
In view of these results, we decided to choose catalyst K to 





Table 1. Optimization of the catalyst.  
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Entry[a] Catalyst (5 
mol %) 




Ee of the E 
isomer (%) [d] 
1 A 4 72 2:1 70 
2 B 5 70 2.2:1 47 
3 C 6 69 1.1:1 69 
4 D 4 73 2.3:1 59[e] 
5 E 5 62 4:1 41[e] 
6 F 5 55 3:1 31 
7 G 3 53 7:1 52[e] 
8 H 5 71 14:1 50 
9 I 5 54 4:1 33[e] 
10 J 7 50 12:1 53 
11 K 5 72 16:1 54 
12 L 8 78 >20:1 10 
[a] Reaction conditions: 0.05 mmol 1a, 0.1 mmol 2a and catalyst (5 mol%) 
in toluene (1 mL) at rt. [b] Isolated yield after column chromatography. [c] 
E:Z ratio determined by 1H NMR of the crude reaction mixture. [d] 
Enantiomeric excess determined by chiral HPLC. [e] Opposite enantiomer. 






Therefore, a wide survey of solvents was tested for the SNV 
reaction between 1a and 2a using 5 mol% of catalyst K. First, 
different aromatic solvents such toluene, benzene, o-xylene, p-
xylene, and (trifluoromethyl)benzene were evaluated obtaining 
product 3aa with high E:Z ratio and good enantiomeric excess, 
being the best solvent benzene (80% yield, 16:1 E:Z ratio, 66% 
ee, entry 2). Chlorinated solvents such CH2Cl2 and CHCl3 were 
less efficient (entries 6 and 7, respectively). Also ethereal solvents 
such Et2O, THF and dioxane gave bad results in terms of 
enantioselectivity. However, when MTBE was used as a solvent 
(entry 11, Table 2) an excellent 98% yield, excellent >20:1 E:Z 
ratio and 64% ee was obtained. Other polar solvents such EtOAc 
or CH3CN and protic solvents such as iPrOH, gave poor results.  
In view of these results, we decided to choose benzene and 
MTBE as solvents to further study of the optimization of the 
reaction conditions. 
 

































Entry[a] Solvent t (h) Yield (%)[b] E:Z ratio [c] Ee of the E 
isomer (%) [d] 
1 toluene 5 72 16:1 54 
2 benzene 7 80 16:1 66 
3 p-xylene 5 63 12:1 59 
4 o-xylene 5 69 15:1 58 
5 PhCF3 2 65 15:1 56 
6 CH2Cl2 24 62 9:1 28 
7 CHCl3 24 65 10:1 40 
8 Et2O 2 78 8:1 25 
9 THF 1 86 8:1 23 
10 dioxane 1 97 20:1 33 
11 MTBE 5 98 >20:1 64 
12 EtOAc 5 92 15:1 56 
13 CH3CN 5 62 13:1 2 
14 i-PrOH 24 77 8:1 15 
[a] Reaction conditions: 0.05 mmol 1a, 0.1 mmol 2a and catalyst (5 mol%) 
in solvent (1 mL) at rt. [b] Isolated yield after column chromatography. [c] E:Z 
ratio determined by 1H NMR of the crude reaction mixture. [d] Enantiomeric 
excess determined by chiral HPLC. 
 
Next, we evaluated the catalyst loading used in the 
asymmetric SNV reaction (Table 3). When a catalyst loading of 10 
mol% was used, lower enantioselectivity was obtained (entry 2), 
while when 2 mol% of catalyst was used lower yield of compound 
3aa was achieved, observing similar enantioselectivity (entries 3). 
We also observed a decrease in the enantioselectivity of the 
reaction when MTBE was used as solvent (entries 5 and 6). 
Moreover, the concentration of the reaction mixture was 
evaluated (entries 7 and 8), observing lower enantioselectivities. 
At this point, we decided to study mixtures of benzene:MTBE as 
solvent to perform the reaction (entries 9 and 10). When 1 mL of 
a mixture benzene:MTBE (0.7:0.3) was used, the corresponding 
product 3aa was obtained with 97% yield, excellent >20:1 E:Z 
ratio and the best enantioselectivity (68% ee). Finally, by lowering 
the reaction temperature to 4 ºC (entry 11), the enantioselectivity 
decreased to 64% ee.  
 





































Ee of the E 
isomer (%) [d] 
1 benzene 7 80 16:1 66 
2[e] benzene 2 88 16:1 57 
3[f] benzene 6 67 16:1 65 
4 MTBE 5 98 >20:1 64 
5[e] MTBE 1 90 >20:1 48 
6[f] MTBE 7 78 20:1 50 
7[g] benzene 2 81 15:1 58 
8[h] benzene 7 90 17:1 55 
9 benzene:MTBE 
(1:1) 
1 88 >20:1 64 
10 benzene:MTBE 
(0.7:0.3) 
1 97 >20:1 68 
11[i] benzene:MTBE 
(0.7:0.3) 
7 63 >20:1 64 
[a] Reaction conditions: 0.05 mmol 1a, 0.1 mmol 2a and catalyst (5 mol%) 
in solvent (1 mL) at rt. [b] Isolated yield after column chromatography. [c] E:Z 
ratio determined by 1H NMR of the crude reaction mixture. [d] Enantiomeric 
excess determined by chiral HPLC. [e] 10 mol% of catalyst K was used. [f] 
2.5 mol% of catalyst K was used. [g] 2 mL of benzene was used. [h] 0.5 mL 
of benzene was used. [i] The reaction was performed at 4 ºC. 





With the optimized reaction conditions in hand (entry 10, 
Table 3), we proceeded to study the scope of the enantioselective 
addition of pyrazolones 2 to isatin-derived nitroalkenes 1 through 
a SNV reaction (Scheme 2). Electron-donating (MeO, Me) or 
electron-withdrawing (Cl), were tolerated at the 5, 6 or 7 position 
of the isatin-derived nitroalkene, affording the corresponding 
products (3ba-3da) with good yields, excellent E:Z ratios and 
good enantiomeric excesses (up to 78% ee). Next, the N-
substitution of the oxindole nitrogen was evaluated (3ea-3ia). 
Groups such as methyl, allyl and propargyl were well 
accommodated, obtaining the corresponding 3-alkylidene-2-
oxindoles 3 with better enantioselectivities (up to 78% ee). Non-
protected NH on the oxindole ring was also tolerated (3ha), 
although with lower yield, diastereoselectivity (10:1 E:Z ratio) and 
enantioselectivity (54% ee). Different pyrazolones 2 were also 
evaluated in the reaction with nitroalkenes 1. The reaction 
proceeded efficiently with high yields and excellent 
diastereoselectivity, although with lower enantioselectivity (53-

































































3ea,a 87% (93%) yield,









3fa, 76% yield, >20:1 dr, 73% ee 












































































Scheme 2. Scope of the enantioselective addition of 4-substituted-pyrazolones 
to isatin-derived nitroalkenes. Reaction conditions: 0.05 mmol 1, 0.1 mmol 2 
and catalyst K (5 mol %) in benzene (0.7 mL):MTBE (0.3 mL). Isolated yield 
after column chromatography. E:Z ratio determined by 1H NMR of the crude 
mixture. Enantiomeric excess determined by chiral HPLC. a The results in 
parenthesis corresponds to the 1 mmol scale reaction.  
The configuration of the double bond in compound 3fa was 
determined as E and the absolute configuration of the stereogenic 
center was determined to be (S) on the basis of X-ray 
crystallographic analysis (Figure 2); the configuration of the rest 









Figure 2. X-ray crystal structure of 3fa. 
On the basis of the absolute configuration of 3fa, we propose a 
plausible mechanism for the stereoselective SNV reaction as is 
shown in the Scheme 3. By the action of one quinuclidine moieties 
of (DHQ)2Pyr, the pyrazol-3-one 2 is activated by hydrogen 
bonding, for the regioselective nucleophilic addition of the 
pyrazol-3-one to the α-position of nitroalkene 1, that could be 
coordinated to the catalyst by π-π stacking interactions. After the 
nucleophilic addition of 2, the intermediate  switches to an 
eclipsed conformation, which is favored by an intramolecular 
hydrogen bond between the nitro group and the hydrogen of the 
C-3 of oxindole through a five-membered ring.[13,14] In this case, in 
the presence of a base (the quinuclidine moiety of the (DHQ)2Pyr 
catalyst), the hydrogen bond prompts a fast 1,2-cis-elimination to 

























































Scheme 3. Plausible reaction mechanism. 






We have developed a catalytic enantioselective addition of 4-
substituted-pyrazolones to isatin-derived nitroalkenes catalyzed 
by (DHQ)2Pyr, obtaining chiral pyrazolones bearing a quaternary 
stereocenter at 4 position with a 3-alkylidene-2-oxindole moiety 
with excellent yields (up to 97%), excellent E:Z ratio (up to >20:1) 
and moderate enantioselectivities (up to 78% ee). The reaction 
consists in a regioselective nucleophilic vinylic substitution (SNV), 
where the nitro group acts as leaving group for delivering 3-
alkylidene-2-oxindoles. The enantioselectivities are moderate, 
however taking into account that we obtain one of the several 
possible isomers, the present methodology represents an 
interesting synthetic way to obtain chiral 3-alkylidene-2-oxindoles. 
An advantage of our system is that the organocatalyst is 
commercially available and the reaction conditions are mild. 
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Excellent diastereoselectivities (10:1 to >20:1 E:Z ratio)
Moderate enantioselectivities (52-78 % ee)  
